Journal
JOURNAL OF ALZHEIMERS DISEASE
Volume 20, Issue 1, Pages 135-143Publisher
IOS PRESS
DOI: 10.3233/JAD-2010-1353
Keywords
Alzheimer's disease; amyloid-beta specific nAbs; immunotherapy for AD; IVIG
Categories
Ask authors/readers for more resources
Intravenous immunoglobulins (IVIG) are currently used for therapeutic purposes in autoimmune disorders. Recently, we demonstrated the presence of naturally occurring antibodies against amyloid-beta (nAbs-A beta) within the pool of IVIG. In this study, we compared different brands of IVIG for nAbs-A beta and have found differences in the specificity of the nAbs-A beta towards A beta(1-40) and A beta(1-42). We analyzed the influence of a pH-shift over the course of antibody storage using ELISA and investigated antibody dimerization at acidic and neutral pH as well as differences in the IgG subclass distributions among the IVIG using both HPLC and a nephelometric assay. Furthermore, we investigated the epitope region of purified nAbs-A beta. The differences found in A beta specificity are not directly proportionate to the binding nature of these antibodies when administered in vivo. This information, however, may serve as a guide when choosing the commercial source of IVIG for therapeutic applications in Alzheimer's disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available